Safety assessment and immunogenicity of a cell-culture-derived influenza vaccine in adults and elderly subjects over three successive influenza seasons

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 5, 2012, Pages 645-652

  Szymczakiewicz Multanowska, Agnieszka ^a   Lattanzi, Maria ^b   Izu, Allen ^b   Casula, Daniela ^b   Sparacio, Maria Vittoria ^b   Kovacs, Csaba ^b   Groth, Nicola ^b  

^a PRA International   (Poland)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Adults; Cell culture derived vaccine; Concomitant vaccines; Elderly; Immunogenicity; Influenza vaccine; Pneumococcal vaccine; Safety

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FATIGUE; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MONOTHERAPY; MYALGIA; NORMAL HUMAN; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REACTOGENICITY; REVACCINATION; SEASON; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL CULTURE TECHNIQUES; DRUG TOXICITY; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84863652916     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19493     Document Type: Article

References (24)

1. Influenza vaccines. Wkly Epidemiol Rec 2005; 80:279- 87; PMID:16171031.
2. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al.; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1-60; PMID:18685555.
3. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaño LF, Nichol KL, et al. Influenza control in the 21st century: Optimizing protection of older adults. Vaccine 2009; 27:5043-53; PMID:19559118; http:// dx.doi.org/10.1016/j. vaccine.2009.06.032.
4. Bridges CB, Katz JM, Levandowski RA and NJ C. Inactivated influenza vaccines. 5 ed. Philadelphia: Saunders, 2008
5. (Plotkin SA, Orenstein WA and PA O, eds. Vaccines)
6. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006; 24:1377-83; PMID:17093488; http://dx.doi. org/10.1038/nbt1261.
7. Wright PF. Vaccine preparedness - are we ready for the next influenza pandemic? N Engl J Med 2008; 358:2540-3; PMID:18550873; http://dx.doi. org/10.1056/NEJMp0803650.
8. Mabrouk T, Ellis RW. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine). Dev Biol (Basel) 2002; 110:125-34; PMID:12477315.
9. (WHO) WHO. Influenza. Fact sheet No. 211. 2003. Available at: http://www.who.int/mediacentre/factsheets/ fs211/en/. Accessed 5 august 2010.
10. Belshe RB. Translational research on vaccines: influenza as an example. Clin Pharmacol Ther 2007; 82:745-9; PMID:17971813; http://dx.doi.org/10.1038/sj. clpt.6100419.
11. Halperin SA, Smith B, Mabrouk T, Germain M, Trépanier P, Hassell T, et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culturederived influenza vaccine in healthy adults, seniors, and children. Vaccine 2002; 20:1240-7; PMID:11803087; http://dx.doi.org/10.1016/S0264-410X(01) 00428-5.
12. Kistner O, Barrett PN, Mundt W, Reiter M, Schober- Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998; 16:960-8; PMID:9682344; http:// dx.doi.org/10.1016/S0264- 410X(97)00301-0.
13. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996; 18:64-76; PMID:8877331.
14. Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine. Vaccine 2009; 27:6022-9; PMID:19666152; http:// dx.doi.org/10.1016/j.vaccine.2009.07. 083.
15. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009; 8:679-88; PMID:19485748; http://dx.doi.org/10.1586/erv.09.31.
16. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 2009; 27:786-91; PMID:19027046; http://dx.doi. org/10.1016/j.vaccine.2008.11.003.
17. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J Infect Dis 2009; 200:849-57; PMID:19673652; http://dx.doi. org/10.1086/605506.
18. Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J Infect Dis 2009; 200:841-8; PMID:19673651; http://dx.doi. org/10.1086/605505.
19. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, et al. Clinical efficacy of cell culture-derived and egg derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010; 51:997-1004; PMID:20868284; http:// dx.doi.org/10.1086/656578.
20. Keitel W, Groth N, Lattanzi M, Praus M, Hilbert AK, Borkowski A, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010; 28:840-8; PMID:19835829; http:// dx.doi.org/10.1016/j.vaccine.2009.10.019.
21. Perucchini E, Consonni S, Sandrini MC, Bergamaschini L, Vergani C. Adverse reactions to influenza vaccine alone or with pneumococcal vaccine in the elderly. J Am Geriatr Soc 2004; 52:1219-20; PMID:15209671; http://dx.doi.org/ 10.1111/j.1532-5415.2004.52327-5.x.
22. Grilli G, Fuiano L, Biasio LR, Pregliasco F, Plebani A, Leibovitz M, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. Eur J Epidemiol 1997; 13:287-91; PMID:9258527; http:// dx.doi.org/10.1023/A: 1007398606807.
23. De Stefano F, Richard A, Goodman MD et al. Simultaneous Administration of influenza and pneumococcal vaccines. JAMA 1982.247: 2551- 2554; http:// dx.doi.org/10.1001/jama.1982.03320430055032.
24. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. CPMP/ BWP/214/96. 12 March, 1997. Available at http:// www.emea.europa.eu/pdfs/human/bwp/021496en. pdf. Accessed 5 august 2010.